Synchronous clonally related anaplastic large cell lymphoma and malignant histiocytosis
Background Synchronous malignant histiocytoses are rare conditions that occur concurrently with another hematologic neoplasm. Most reported cases are associated with B-cell lymphoproliferative disorders, while associations with T-cell hemopathies are less common. These two diseases may share mutatio...
Gespeichert in:
Veröffentlicht in: | Diagnostic Pathology 2025, Vol.20 (1) |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Report |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | 1 |
container_start_page | |
container_title | Diagnostic Pathology |
container_volume | 20 |
creator | Harb, Mirvate Abrassart, Tom Dewispeleare, Laurent Sidon, Pierre Dirckx, Natacha Trepant, Anne-laure Castiaux, Julie Heimann, Pierre Emile, Jean-Francois Farhat, Hussein |
description | Background Synchronous malignant histiocytoses are rare conditions that occur concurrently with another hematologic neoplasm. Most reported cases are associated with B-cell lymphoproliferative disorders, while associations with T-cell hemopathies are less common. These two diseases may share mutations and/or cytogenetic anomalies, which can lead to malignant proliferations. In such cases, the term "secondary malignant histiocytosis" can be applied. Case description A 26-year-old patient was diagnosed with anaplastic lymphoma kinase negative anaplastic large cell lymphoma [ALK-ALCL] associated with synchronous malignant histiocytosis. Neoplastic cells were distinguished by the exclusivity of the rearrangement of TCR genes within the lymphoma cells, whereas mutations in the KRAS and TP53 genes affected mono-histiocytic cells. However, these two cells populations shared common chromosomal abnormalities. First line treatment protocol included Brentuximab vedotin, cyclophosphamide, doxorubicin, and methylprednisolone. Despite a partial clinical and biological response after cycle 1 of treatment, the patient was refractory at the end of cycle 2. Patient died in the intensive care unit from a multiple-organ failure related to lymphohistiocytic hemophagocytosis. Conclusion This case represents the first documented instance of synchronous malignant histiocytosis associated with anaplastic large cell lymphoma. Notably, the uniqueness of this case lies in the absence of TCR rearrangement in the histiocytic cells, despite the presence of shared chromosomal abnormalities with the lymphomatous cells indicating a common origin for both neoplastic proliferations. Considering the rarity of such occurrences, the use of histiocytosis targeted therapy alongside conventional lymphoma treatment warrants consideration in such a context. Keywords: Secondary malignant histiocytosis, Synchronous malignant histiocytosis, Anaplastic large cell lymphoma, Case report |
doi_str_mv | 10.1186/s13000-025-01597-3 |
format | Report |
fullrecord | <record><control><sourceid>gale</sourceid><recordid>TN_cdi_gale_infotracacademiconefile_A823600813</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A823600813</galeid><sourcerecordid>A823600813</sourcerecordid><originalsourceid>FETCH-gale_infotracacademiconefile_A8236008133</originalsourceid><addsrcrecordid>eNqVSzmOwjAUtRBIrBeg8gUM3zFZKEdoED0jTYm-HCcx-rGj2FPk9rigoB294u2M7SUcpKyKY5AKAARkuQCZn0uhZmwly1MhkivmH3rJ1iE8AU55nsGK_d4np7vRO_8XuCbvkGjioyGMpubocCAM0WpOOLaGa0PEaeqHzveY6pr3SLZ16CLvbBp6PUUfbNiyRYMUzO7NG3a4fv9cbqJFMg_rGh9H1Am16a32zjQ25V9VpgqASir178ML_o1R3A</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>report</recordtype></control><display><type>report</type><title>Synchronous clonally related anaplastic large cell lymphoma and malignant histiocytosis</title><source>Springer Nature - Complete Springer Journals</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><creator>Harb, Mirvate ; Abrassart, Tom ; Dewispeleare, Laurent ; Sidon, Pierre ; Dirckx, Natacha ; Trepant, Anne-laure ; Castiaux, Julie ; Heimann, Pierre ; Emile, Jean-Francois ; Farhat, Hussein</creator><creatorcontrib>Harb, Mirvate ; Abrassart, Tom ; Dewispeleare, Laurent ; Sidon, Pierre ; Dirckx, Natacha ; Trepant, Anne-laure ; Castiaux, Julie ; Heimann, Pierre ; Emile, Jean-Francois ; Farhat, Hussein</creatorcontrib><description>Background Synchronous malignant histiocytoses are rare conditions that occur concurrently with another hematologic neoplasm. Most reported cases are associated with B-cell lymphoproliferative disorders, while associations with T-cell hemopathies are less common. These two diseases may share mutations and/or cytogenetic anomalies, which can lead to malignant proliferations. In such cases, the term "secondary malignant histiocytosis" can be applied. Case description A 26-year-old patient was diagnosed with anaplastic lymphoma kinase negative anaplastic large cell lymphoma [ALK-ALCL] associated with synchronous malignant histiocytosis. Neoplastic cells were distinguished by the exclusivity of the rearrangement of TCR genes within the lymphoma cells, whereas mutations in the KRAS and TP53 genes affected mono-histiocytic cells. However, these two cells populations shared common chromosomal abnormalities. First line treatment protocol included Brentuximab vedotin, cyclophosphamide, doxorubicin, and methylprednisolone. Despite a partial clinical and biological response after cycle 1 of treatment, the patient was refractory at the end of cycle 2. Patient died in the intensive care unit from a multiple-organ failure related to lymphohistiocytic hemophagocytosis. Conclusion This case represents the first documented instance of synchronous malignant histiocytosis associated with anaplastic large cell lymphoma. Notably, the uniqueness of this case lies in the absence of TCR rearrangement in the histiocytic cells, despite the presence of shared chromosomal abnormalities with the lymphomatous cells indicating a common origin for both neoplastic proliferations. Considering the rarity of such occurrences, the use of histiocytosis targeted therapy alongside conventional lymphoma treatment warrants consideration in such a context. Keywords: Secondary malignant histiocytosis, Synchronous malignant histiocytosis, Anaplastic large cell lymphoma, Case report</description><identifier>ISSN: 1746-1596</identifier><identifier>EISSN: 1746-1596</identifier><identifier>DOI: 10.1186/s13000-025-01597-3</identifier><language>eng</language><publisher>BioMed Central Ltd</publisher><subject>Cancer ; Cytogenetics ; Genetic aspects ; Health aspects ; Histiocytosis ; Non-Hodgkin's lymphomas ; T cells ; Tumor proteins</subject><ispartof>Diagnostic Pathology, 2025, Vol.20 (1)</ispartof><rights>COPYRIGHT 2025 BioMed Central Ltd.</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>776,780,860,4476,27902</link.rule.ids></links><search><creatorcontrib>Harb, Mirvate</creatorcontrib><creatorcontrib>Abrassart, Tom</creatorcontrib><creatorcontrib>Dewispeleare, Laurent</creatorcontrib><creatorcontrib>Sidon, Pierre</creatorcontrib><creatorcontrib>Dirckx, Natacha</creatorcontrib><creatorcontrib>Trepant, Anne-laure</creatorcontrib><creatorcontrib>Castiaux, Julie</creatorcontrib><creatorcontrib>Heimann, Pierre</creatorcontrib><creatorcontrib>Emile, Jean-Francois</creatorcontrib><creatorcontrib>Farhat, Hussein</creatorcontrib><title>Synchronous clonally related anaplastic large cell lymphoma and malignant histiocytosis</title><title>Diagnostic Pathology</title><description>Background Synchronous malignant histiocytoses are rare conditions that occur concurrently with another hematologic neoplasm. Most reported cases are associated with B-cell lymphoproliferative disorders, while associations with T-cell hemopathies are less common. These two diseases may share mutations and/or cytogenetic anomalies, which can lead to malignant proliferations. In such cases, the term "secondary malignant histiocytosis" can be applied. Case description A 26-year-old patient was diagnosed with anaplastic lymphoma kinase negative anaplastic large cell lymphoma [ALK-ALCL] associated with synchronous malignant histiocytosis. Neoplastic cells were distinguished by the exclusivity of the rearrangement of TCR genes within the lymphoma cells, whereas mutations in the KRAS and TP53 genes affected mono-histiocytic cells. However, these two cells populations shared common chromosomal abnormalities. First line treatment protocol included Brentuximab vedotin, cyclophosphamide, doxorubicin, and methylprednisolone. Despite a partial clinical and biological response after cycle 1 of treatment, the patient was refractory at the end of cycle 2. Patient died in the intensive care unit from a multiple-organ failure related to lymphohistiocytic hemophagocytosis. Conclusion This case represents the first documented instance of synchronous malignant histiocytosis associated with anaplastic large cell lymphoma. Notably, the uniqueness of this case lies in the absence of TCR rearrangement in the histiocytic cells, despite the presence of shared chromosomal abnormalities with the lymphomatous cells indicating a common origin for both neoplastic proliferations. Considering the rarity of such occurrences, the use of histiocytosis targeted therapy alongside conventional lymphoma treatment warrants consideration in such a context. Keywords: Secondary malignant histiocytosis, Synchronous malignant histiocytosis, Anaplastic large cell lymphoma, Case report</description><subject>Cancer</subject><subject>Cytogenetics</subject><subject>Genetic aspects</subject><subject>Health aspects</subject><subject>Histiocytosis</subject><subject>Non-Hodgkin's lymphomas</subject><subject>T cells</subject><subject>Tumor proteins</subject><issn>1746-1596</issn><issn>1746-1596</issn><fulltext>true</fulltext><rsrctype>report</rsrctype><creationdate>2025</creationdate><recordtype>report</recordtype><sourceid/><recordid>eNqVSzmOwjAUtRBIrBeg8gUM3zFZKEdoED0jTYm-HCcx-rGj2FPk9rigoB294u2M7SUcpKyKY5AKAARkuQCZn0uhZmwly1MhkivmH3rJ1iE8AU55nsGK_d4np7vRO_8XuCbvkGjioyGMpubocCAM0WpOOLaGa0PEaeqHzveY6pr3SLZ16CLvbBp6PUUfbNiyRYMUzO7NG3a4fv9cbqJFMg_rGh9H1Am16a32zjQ25V9VpgqASir178ML_o1R3A</recordid><startdate>20250114</startdate><enddate>20250114</enddate><creator>Harb, Mirvate</creator><creator>Abrassart, Tom</creator><creator>Dewispeleare, Laurent</creator><creator>Sidon, Pierre</creator><creator>Dirckx, Natacha</creator><creator>Trepant, Anne-laure</creator><creator>Castiaux, Julie</creator><creator>Heimann, Pierre</creator><creator>Emile, Jean-Francois</creator><creator>Farhat, Hussein</creator><general>BioMed Central Ltd</general><scope/></search><sort><creationdate>20250114</creationdate><title>Synchronous clonally related anaplastic large cell lymphoma and malignant histiocytosis</title><author>Harb, Mirvate ; Abrassart, Tom ; Dewispeleare, Laurent ; Sidon, Pierre ; Dirckx, Natacha ; Trepant, Anne-laure ; Castiaux, Julie ; Heimann, Pierre ; Emile, Jean-Francois ; Farhat, Hussein</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-gale_infotracacademiconefile_A8236008133</frbrgroupid><rsrctype>reports</rsrctype><prefilter>reports</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Cancer</topic><topic>Cytogenetics</topic><topic>Genetic aspects</topic><topic>Health aspects</topic><topic>Histiocytosis</topic><topic>Non-Hodgkin's lymphomas</topic><topic>T cells</topic><topic>Tumor proteins</topic><toplevel>online_resources</toplevel><creatorcontrib>Harb, Mirvate</creatorcontrib><creatorcontrib>Abrassart, Tom</creatorcontrib><creatorcontrib>Dewispeleare, Laurent</creatorcontrib><creatorcontrib>Sidon, Pierre</creatorcontrib><creatorcontrib>Dirckx, Natacha</creatorcontrib><creatorcontrib>Trepant, Anne-laure</creatorcontrib><creatorcontrib>Castiaux, Julie</creatorcontrib><creatorcontrib>Heimann, Pierre</creatorcontrib><creatorcontrib>Emile, Jean-Francois</creatorcontrib><creatorcontrib>Farhat, Hussein</creatorcontrib></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Harb, Mirvate</au><au>Abrassart, Tom</au><au>Dewispeleare, Laurent</au><au>Sidon, Pierre</au><au>Dirckx, Natacha</au><au>Trepant, Anne-laure</au><au>Castiaux, Julie</au><au>Heimann, Pierre</au><au>Emile, Jean-Francois</au><au>Farhat, Hussein</au><format>book</format><genre>unknown</genre><ristype>RPRT</ristype><atitle>Synchronous clonally related anaplastic large cell lymphoma and malignant histiocytosis</atitle><jtitle>Diagnostic Pathology</jtitle><date>2025-01-14</date><risdate>2025</risdate><volume>20</volume><issue>1</issue><issn>1746-1596</issn><eissn>1746-1596</eissn><abstract>Background Synchronous malignant histiocytoses are rare conditions that occur concurrently with another hematologic neoplasm. Most reported cases are associated with B-cell lymphoproliferative disorders, while associations with T-cell hemopathies are less common. These two diseases may share mutations and/or cytogenetic anomalies, which can lead to malignant proliferations. In such cases, the term "secondary malignant histiocytosis" can be applied. Case description A 26-year-old patient was diagnosed with anaplastic lymphoma kinase negative anaplastic large cell lymphoma [ALK-ALCL] associated with synchronous malignant histiocytosis. Neoplastic cells were distinguished by the exclusivity of the rearrangement of TCR genes within the lymphoma cells, whereas mutations in the KRAS and TP53 genes affected mono-histiocytic cells. However, these two cells populations shared common chromosomal abnormalities. First line treatment protocol included Brentuximab vedotin, cyclophosphamide, doxorubicin, and methylprednisolone. Despite a partial clinical and biological response after cycle 1 of treatment, the patient was refractory at the end of cycle 2. Patient died in the intensive care unit from a multiple-organ failure related to lymphohistiocytic hemophagocytosis. Conclusion This case represents the first documented instance of synchronous malignant histiocytosis associated with anaplastic large cell lymphoma. Notably, the uniqueness of this case lies in the absence of TCR rearrangement in the histiocytic cells, despite the presence of shared chromosomal abnormalities with the lymphomatous cells indicating a common origin for both neoplastic proliferations. Considering the rarity of such occurrences, the use of histiocytosis targeted therapy alongside conventional lymphoma treatment warrants consideration in such a context. Keywords: Secondary malignant histiocytosis, Synchronous malignant histiocytosis, Anaplastic large cell lymphoma, Case report</abstract><pub>BioMed Central Ltd</pub><doi>10.1186/s13000-025-01597-3</doi></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1746-1596 |
ispartof | Diagnostic Pathology, 2025, Vol.20 (1) |
issn | 1746-1596 1746-1596 |
language | eng |
recordid | cdi_gale_infotracacademiconefile_A823600813 |
source | Springer Nature - Complete Springer Journals; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access; Springer Nature OA Free Journals |
subjects | Cancer Cytogenetics Genetic aspects Health aspects Histiocytosis Non-Hodgkin's lymphomas T cells Tumor proteins |
title | Synchronous clonally related anaplastic large cell lymphoma and malignant histiocytosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-19T17%3A15%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.atitle=Synchronous%20clonally%20related%20anaplastic%20large%20cell%20lymphoma%20and%20malignant%20histiocytosis&rft.jtitle=Diagnostic%20Pathology&rft.au=Harb,%20Mirvate&rft.date=2025-01-14&rft.volume=20&rft.issue=1&rft.issn=1746-1596&rft.eissn=1746-1596&rft_id=info:doi/10.1186/s13000-025-01597-3&rft_dat=%3Cgale%3EA823600813%3C/gale%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_galeid=A823600813&rfr_iscdi=true |